DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
CERC-301 is an investigational drug.
There have been 6 clinical trials for CERC-301. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Cerecor Inc, Yale University, and Icahn School of Medicine at Mount Sinai.
There are six US patents protecting this investigational drug and seventy-nine international patents.
Recent Clinical Trials for CERC-301
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Cerecor Inc||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||National Institute on Drug Abuse (NIDA)||Phase 2|
|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?||Office of Research on Women's Health (ORWH)||Phase 2|
Top disease conditions for CERC-301
Top clinical trial sponsors for CERC-301
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CERC-301||See Pricing||Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists||Rugen Holdings (Cayman) Limited (Grand Cayman, KY)||See Pricing|
|CERC-301||See Pricing||Compounds, compositions and methods||CERECOR, INC. (Baltimore, MD) MERCK SHARP & DOHME CORP. (Rahway, NJ)||See Pricing|
|CERC-301||See Pricing||3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists||RUGEN HOLDINGS (CAYMAN) LIMITED (Grand Cayman, KY)||See Pricing|
|CERC-301||See Pricing||3-fluoro-piperidines as NMDA/NR2B antagonists||Merck & Co., Inc. (Rahway, NJ)||See Pricing|
|CERC-301||See Pricing||Methods for treating Parkinson's disease||UCB Biopharma SPRL (Brussels, BE)||See Pricing|
|CERC-301||See Pricing||Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists||Rugen Holdings (Cayman) Limited (Grand Cayman, KY)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|CERC-301||European Patent Office||3152213||2034-06-04||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|